Bliss GVS Pharma shareholders approve Santosh Parab director appointment

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Santosh Parab appointed as Non-Executive Non-Independent Director via postal ballot
  • Total votes in favour stood at 60,481,459, representing 97.04% of votes polled
  • Public institutions recorded 15.53% opposition, contrasting with near-unanimous retail support
  • Voting period ran from August 21, 2026, to September 19, 2026, via CDSL e-voting
powered bylight_fuzz_icon
51619822

*this image is generated using AI for illustrative purposes only.

Bliss GVS Pharma shareholders approved the appointment of Santosh Parab as a Non-Executive and Non-Independent Director through a postal ballot process concluded on September 22, 2026.

The resolution, passed as an Ordinary Resolution, received overwhelming support from the voting base. Out of the total votes polled, 60,481,459 were cast in favour, while 1,841,768 votes were against. This resulted in a favourable vote percentage of 97.04% on the total votes polled.

The voting period for the remote e-voting facility, provided by Central Depository Services (India) Limited, commenced on August 21, 2026, and ended on September 19, 2026. The scrutinizer’s report was submitted by Vijay Yadav of M/s. AVS & Associates, confirming the compliance with the Companies Act, 2013, and SEBI listing regulations.

Voting breakdown by shareholder category

The voting results reveal distinct patterns in participation and support across different shareholder groups. Promoters and promoter group members voted unanimously in favour, while public institutional holders showed notable dissent.

Category Shares Held Votes Polled Votes For Votes Against % In Favour
Promoter and Promoter Group 3,71,30,124 3,24,37,024 3,24,37,024 0 100.00%
Public Institutions 1,69,39,697 1,18,54,291 1,00,13,243 18,41,048 84.47%
Public Non-Institutions 5,21,74,151 1,80,31,912 1,80,31,192 720 99.99%
Total 10,62,43,972 6,23,23,227 6,04,81,459 1,841,768 97.04%

What the numbers show

A divergence exists between institutional and retail sentiment regarding the director appointment. While Public Non-Institutional shareholders (retail investors) voted overwhelmingly in favour with only 720 dissenting votes out of over 18 million polled, Public Institutional holders recorded a significant 15.53% opposition rate. This suggests that institutional investors may have had specific concerns or governance considerations that differed from the broader retail base, although the overall resolution passed comfortably due to strong promoter backing.

Historical Stock Returns for Bliss GVS Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+5.00%-3.65%+19.94%+230.40%+361.44%+521.01%

What specific governance or strategic concerns drove the 15.53% dissent among public institutional shareholders regarding Santosh Parab's appointment?

How might Parab's role as a Non-Executive, Non-Independent Director influence Bliss GVS Pharma's upcoming capital allocation or M&A strategies?

Will the notable institutional opposition trigger further scrutiny or activism from proxy advisory firms in future shareholder votes?

Bliss GVS Pharma seeks shareholder approval for Santosh Parab director role

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Bliss GVS Pharma seeks shareholder approval for Santosh Parab's director appointment
  • Parab will serve as non-executive, non-independent director
  • Remote e-voting opens August 21, 2026, and closes September 19, 2026
  • Results to be declared on or before September 22, 2026
powered bylight_fuzz_icon
48773527

*this image is generated using AI for illustrative purposes only.

Bliss GVS Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Santosh Parab as a director. The resolution aims to formalize his role as a non-executive, non-independent director following his initial appointment as an additional director on July 3, 2026.

The company’s Board of Directors approved the appointment based on the recommendation of the Nomination and Remuneration Committee. Mr. Parab, a Chartered Accountant with over 35 years of experience in audit, taxation, and corporate finance, brings expertise from previous roles at State Bank of India, ICICI Bank, and Kotak Mahindra Bank. He currently holds 2,300 equity shares in the company.

Voting Process and Timeline

Shareholders holding shares as of the cut-off date, August 14, 2026, are eligible to vote via the remote e-voting facility provided by Central Depository Services (India) Limited (CDSL). The voting window is strictly defined:

  • Start Date: August 21, 2026, at 9:00 am
  • End Date: September 19, 2026, at 5:00 pm
  • Result Declaration: On or before September 22, 2026

The company will not dispatch physical ballot forms. Notices have been sent electronically to members with registered email addresses through the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.

Governance Details

Mr. Vijay Yadav, Partner at AVS & Associates, has been appointed as the scrutinizer for the postal ballot process. His report on the validity of votes cast will be final. The resolution requires an ordinary majority for passage.

Mr. Parab is not related to any other director or key managerial personnel of the company. He attended one board meeting during the fiscal year 2025-26 prior to this appointment. The board stated that his continued association would strengthen governance and support long-term strategic objectives.

Historical Stock Returns for Bliss GVS Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+5.00%-3.65%+19.94%+230.40%+361.44%+521.01%

How might Santosh Parab's extensive banking and finance background influence Bliss GVS Pharma's capital structure or debt management strategies?

What specific long-term strategic objectives has the board outlined that require the specialized expertise of a non-executive director with audit and taxation experience?

Could the appointment of an additional non-independent director signal any upcoming changes in the company's corporate governance framework or board composition?

More News on Bliss GVS Pharma

1 Year Returns:+361.44%